Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Summary
In a global, double-blind phase 3 trial (n=2713), fixed-dose cagrilintide–semaglutide 2.4 mg each was superior to semaglutide 2.4 mg for HbA1c reduction, with additional weight benefits. The combination also outperformed lower-dose comparators and maintained treatment through 68 weeks in most participants.
Key Findings
- Large, global, double-blind, randomized trial enrolled 2713 adults with inadequately controlled type 2 diabetes.
- CagriSema 2.4 mg each was superior to semaglutide 2.4 mg for HbA1c reduction; weight outcomes favored CagriSema.
- High treatment persistence through week 68 (87.6% on treatment), supporting long-term use feasibility.
Clinical Implications
For patients needing escalation beyond GLP-1 RA monotherapy, CagriSema offers greater HbA1c and weight reduction; selection should weigh efficacy gains against tolerability and access.
Why It Matters
First large head-to-head phase 3 evidence that an amylin–GLP-1 fixed-dose combination exceeds GLP-1 monotherapy for glycemic control (and weight), shaping future treatment algorithms.
Limitations
- Abstract lacks detailed safety breakdown by comparator arm
- Generalizability to non-trial settings and diverse ancestries still requires real-world validation
Future Directions
Evaluate cardiovascular outcomes, durability after discontinuation, and cost-effectiveness; define positioning versus GLP-1/GIP dual agonists.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Double-blind, randomized, active- and placebo-controlled phase 3 trial
- Study Design
- OTHER